Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

2017 ASCO Annual Meeting
Tweet this page

Gunter von Minckwitz, MD, of the German Breast Group, discusses study findings on a randomized comparison of chemotherapy, trastuzumab, and placebo vs chemotherapy, trastuzumab, and pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer. (Abstract LBA500)

Advertisement

Advertisement



Advertisement